Reglan

Do you want an attorney on your side who has been recognized as one of Dallas/Fort Worth's best lawyers? Rachel Montes will ensure that you will not stand alone in your legal battle. The best legal counsel and affordable help is just one phone call away.

"We have a well-earned reputation for building strong cases and taking them all the way through jury trial when necessary."

Rachel Montes

TARDIVE DYSKINESIA LINKED TO REGLAN USE

ReglanLong term or high dosage use of Reglan (also known as metoclopramide), has been linked to a movement disorder called tardive dyskinesia, which can continue to affect Reglan users even after the drug is discontinued.

In February of 2009, the U.S. Food & Drug Administration (FDA) ordered the maker of Reglan to add a boxed warning about this risk to its label. In lawsuits filed against Wyeth, the manufacturer of Reglan, allegations have been made that Wyeth knew of a widespread tendency among physicians to mis-prescribe Reglan for long periods of time even though the medication is only approved for 12 months of use. REGLAN IS ONLY APPROVED FOR SHORT TERM USE OF PERIODS BETWEEN 4-12 WEEKS.

Click here to read the FDA Warning.

ReglanREGLAN is supposed to be prescribed as a short-term treatment for heartburn caused by gastroesophageal reflux in people who have used other medications without relief of symptoms. REGLAN is also used to treat slow gastric emptying in people with diabetes (also called diabetic gastroparesis), which can cause nausea, vomiting, heartburn, loss of appetite, and a feeling of fullness after meals.

In one study, the FDA found that about 20 percent of patients who used REGLAN, used it for longer than three months, longer than the 12 week period alloted for use of the product. The FDA also claims there were reports of TARDIVE DYSKINESIA in patients who used REGLAN (metoclopramide), and that the majority of those who reported these problems had taken the drug for more than three months.

WHAT IS TARDIVE DYSKINESIA?

Tardive Dyskinesia is horribly disabling condition that is characterized by repetitive, involuntary movements much like Parkinson's, but often times much more pronounced than Parkinsons. Even after the patient stops taking the medication, the side effects not only continue, but in many cases the symptoms actually worsened after the patient discontinued the use of REGLAN. To make matters worse, there is no treatment an no cure for TARDIVE DYSKINESIA.

  1. Were you or a loved one prescribed Reglan® or Metoclopramide?
  2. Have you or loved one been diagnosed with Tardive Dyskinesia?
  3. How long did you or your loved one take Reglan® or Metoclopramide?
  4. Did you or loved one experience any of the following symptoms?
    1. Involuntary/ repetitive movements of the extremities
    2. Facial tics
    3. Lip smacking, pursing and puckering
    4. Face Grimacing
    5. Tongue protrusion
    6. Rapid eye movements or blinking
    7. Impaired movement of the fingers.
    8. Restless Leg Syndrome (RLS)

FREE CASE REVIEW

FDA Warning for Reglan

GLAXOSMITHKLINE RESERVES $2.36 BILLION FOR AVANDIA SETTLEMENTS | Dallas, Texas Personal Injury Attorney Blog

By Team Member | October 27, 2010

GlaxoSmithKline (GSK) CEO Andrew Witty announced that GlaxoSmithKline is under investigation from the Justice Department and several states for actions related to the development and marketing of its diabetes drug Avandia. The company is responding to a subpoena from Justice as well as civil investigative demands from numerous state attorneys general, the company said Thursday.…

GOOD LOOKING DRIVERS CAUSE MORE WRECKS | Dallas, Texas Personal Injury Attorney Blog

By Team Member | October 27, 2010

STUDY REVEALS “FLIRTING WHILE DRIVING” IS A MAJOR DISTRACTION A British survey revealed that 41 percent of drivers admitted to trying to flirt with while on the move, and 15 percent conceded they crashed their car or had a near miss because they were distracted by an attractive passerby. One of the more controversial findings…

US AND ENGLAND HEALTH OFFICIALS DEBATE DANGERS OF AVANDIA | Dallas, Texas Personal Injury Attorney Blog

By Team Member | October 26, 2010

Last week, there was an unplanned debate between high leval health officials of America’s and Britain’s drug regulatory agencies over the role and value of hemoglobin A1c reduction in diabetes drug approval. Janet Woodcock, the Director for the FDA Center for Drug Evaluation and Research and Sir Alasdair Breckenridge, chairman of the UK’s Medicines and…

Ways to Get in Touch

Please enter your name.
Please enter a valid phone number.
Please enter a message.

PHONE: 214-522-9401
FAX: 214-522-9428
CALL TOLL FREE: 877-529-8899

MONTES LAW GROUP, PC
1121 KINWEST PARKWAY, SUITE 100
IRVING, TX 75063

Street View